Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regulus Therapeutics (RGLS) Misses Q4 EPS by 1c
March 2, 2017 4:11 PM ESTRegulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.38), $0.01 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at less than $100 thousand versus $10.9 million last year,
Cash, cash equivalents and short-term investments were $76.1 million at December 31, 2016, compared with $115.3 million at December 31,... More
